Portal vein thrombosis (PVT) is a relatively common complication in patients with liver
cirrhosis, but might also occur in absence of an overt liver disease. Several causes, either …

Portal vein tumor thrombosis (PVTT) is a common phenomenon in hepatocellular carcinoma
(HCC). Compared to HCC without PVTT, HCC with PVTT is characterized by an aggressive …

Hepatocellular carcinoma (HCC) is one of the most common types of cancers and a global
health challenge with a low early diagnosis rate and high mortality. The coagulation …

Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …

The incidence of hepatocellular carcinoma (HCC) is expected to increase in the next 2
decades, largely due to hepatitis C infection and secondary cirrhosis. HCC is being detected …

Purpose To determine the safety and efficacy of transarterial chemoembolization (TACE)
combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular …

Aliment Pharmacol Ther 2010; 32: 1154–1162 Summary Background Reliable
epidemiological data for portal vein thrombosis are lacking. Aims To investigate the …

Purpose To investigate the utility of diffusion-weighted (DW) imaging in distinguishing bland
thrombus from neoplastic thrombus in the portal vein in patients with hepatocellular …

Many patients with hepatocellular carcinoma (HCC) present with advanced disease, not
amenable to curative therapies such as surgery, transplantation or radiofrequency ablation …

Background The aim of this study was to compare the efficacy of hepatic arterial infusion
chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients …